CN111825737A - 胆烷酸共轭物的纯化 - Google Patents
胆烷酸共轭物的纯化 Download PDFInfo
- Publication number
- CN111825737A CN111825737A CN202010267936.6A CN202010267936A CN111825737A CN 111825737 A CN111825737 A CN 111825737A CN 202010267936 A CN202010267936 A CN 202010267936A CN 111825737 A CN111825737 A CN 111825737A
- Authority
- CN
- China
- Prior art keywords
- acid
- formula
- butanol
- tauroursodeoxycholic
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000746 purification Methods 0.000 title claims description 9
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 title description 2
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims abstract description 54
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000002253 acid Substances 0.000 claims description 32
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 15
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 14
- -1 heteroaromatic amine Chemical group 0.000 claims description 14
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 14
- 229960001661 ursodiol Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229960003080 taurine Drugs 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 4
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims description 4
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 3
- 238000010533 azeotropic distillation Methods 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000001587 cholestatic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及以下式(I)的牛磺熊去氧胆酸的纯化方法:
Description
发明的技术领域
本发明涉及牛磺熊去氧胆酸(tauroursodeoxycholic acid)的纯化方法,所述牛磺熊去氧胆酸是在治疗胆汁郁积综合征(cholestatic syndrome)中使用的熊去氧胆酸的牛磺酸共轭物。
发明背景
牛磺熊去氧胆酸,也称为TUDCA,如下面的式(I)所示:
牛磺熊去氧胆酸是一种存在于我们生物体中的胆汁酸,用于治疗胆汁郁积病状,例如原发性胆汁性肝硬化、原发性硬化性胆管炎、与囊性纤维化或肝内家族相关的胆汁郁积、以及胆固醇结石(cholesterol stone)。
在工业规模上,式(I)的牛磺熊去氧胆酸以不同方法制备。最初,所述化合物是从熊胆汁中获得的。目前,式(I)的牛磺熊去氧胆酸是通过以下方法制备的:工业发酵,例如Xu等人在Microb.Cell.Fact(2019)18:34中所述的工业发酵,使用修饰的大肠杆菌(E.coli)细胞;或者,合成,例如用式(II)的熊去氧胆酸为原料合成,
例如如EP 0 629 634或IT 1197330中所述的那样合成。
EP 0 629 634或IT 1197330中所述的方法包括:式(II)的熊去氧胆酸的盐与卤代羰基酯、例如与式(III)的衍生物反应,
Cl-COOR
(III),
其中Cl是氯且R选自C1-C6烷基、苯基或苄基,从而得到式(IV)的混合酸酐
式(IV)的混合酸酐与式(V)的牛磺酸反应,
最后得到式(I)的牛磺熊去氧胆酸。
如此得到的式(I)的牛磺熊去氧胆酸必须与反应期间形成的盐、未反应的式(V)的牛磺酸和胆汁酸、例如与未反应的式(II)的熊去氧胆酸、和/或可任选地存在于反应混合物中的另外的胆汁酸分离。
EP 0 400 695和EP 0 629 634描述了通过色谱法、例如通过使用离子树脂纯化式(I)的牛磺熊去氧胆酸的方法。
IT 1197330中公开的方法是一种式(I)的牛磺熊去氧胆酸的纯化方法,其包括:向反应溶液中加入酸,从而使pH降低至约2,并浓缩该混合物。将所得的残余物溶于乙醇中,通过过滤除去未反应的式(V)的牛磺酸,并通过加入丙酮、乙酸乙酯或其混合物沉淀出式(I)的牛磺熊去氧胆酸。
EP 2 137 206公开了一种将盐和未反应的牛磺酸与式(I)的牛磺熊去氧胆酸的碱金属盐或碱土金属盐分离的方法,其如下进行:加入0.8-1.4当量的酸并使溶液静置10-180分钟。分离沉淀的牛磺酸,随后加入有机溶剂,导致式(I)的牛磺熊去氧胆酸沉淀。
然而,仍然需要找到一种以高产率纯化式(I)的牛磺熊去氧胆酸且特别适合用于工业生产的新的安全的替代方法。特别地,仍然需要一种方法,其不仅使得式(I)的牛磺熊去氧胆酸与反应混合物中存在的盐、特别是未反应的(V)的牛磺酸分离,而且使得式(I)的牛磺熊去氧胆酸与其它胆烷酸例如未反应的式(II)的熊去氧胆酸或作为起始产品中的杂质存在的其它胆烷酸分离。
发明简述
本发明的目的是一种纯化以下式(I)的牛磺熊去氧胆酸或其盐的方法:
其包括:
-用C4-C7醇从水溶液中萃取式(I)的牛磺熊去氧胆酸或其盐;
-加入不同于C4-C7醇的另外的有机溶剂;或者作为所述加入的替代选择,将溶液冷却至低于约5℃的温度、优选冷却至约0℃或更低的温度;
-加入质子酸(HX),以沉淀出式(I)的牛磺熊去氧胆酸,和
-分离式(I)的牛磺熊去氧胆酸。
该方法使得式(I)的牛磺熊去氧胆酸与反应混合物中存在的盐和式(V)的牛磺酸、以及与其它胆烷酸例如式(II)的熊去氧胆酸分离。本文所述的操作使得安全地获得令人惊奇地高度纯的产品,其能符合API所需的监管要求。
发明详述
本发明的目的是一种纯化以下式(I)的牛磺熊去氧胆酸或其盐的方法:
其包括:
-用C4-C7醇从水溶液中萃取式(I)的牛磺熊去氧胆酸或其盐;
-加入不同于C4-C7醇的另外的有机溶剂;或者作为所述加入的替代选择,将溶液冷却至低于约5℃的温度、优选冷却至约0℃或更低的温度;
-加入质子酸(HX),以沉淀出式(I)的牛磺熊去氧胆酸,和
-分离式(I)的牛磺熊去氧胆酸。
式(I)的牛磺熊去氧胆酸的盐优选是可药用盐。可药用盐的实例包括衍生自适宜的碱的盐,例如碱金属盐(例如钠盐或钾盐)、碱土金属盐(例如钙盐或镁盐)、铵盐或NR'4 +,其中R'是C1-C4烷基。
可以将起始的水溶液中的式(I)的牛磺熊去氧胆酸浓缩至0.1%-70%重量/重量、典型地2%-50%重量/重量、例如约5%、10%、20%、30%或40%重量/重量的溶液。
用C4-C7醇从水溶液中萃取使得式(I)的牛磺熊去氧胆酸富集在所述C4-C7醇中;同时,相反地,反应混合物中存在的盐、特别是式(V)的牛磺酸则保留在水相中。
本发明的所述C4-C7醇可以是直链的、支链的或环状的。所述C4-C7醇可以选自例如1-丁醇、仲-丁醇、叔-丁醇、1-戊醇、2-戊醇、3-戊醇、1-环己醇和1-庚醇;优选1-丁醇、仲-丁醇、叔-丁醇和1-环己醇;更优选1-丁醇。
所述不同于C4-C7醇的另外的有机溶剂可以是:极性非质子溶剂,例如二甲基甲酰胺、二甲亚砜或乙腈;醚,例如甲基叔丁基醚、四氢呋喃或二噁烷;酮,例如甲基乙基酮、甲基异丁基酮或丙酮;酯,例如直链或支链的C1-C5醇的乙酸酯,优选乙酸乙酯;氯化溶剂,例如二氯甲烷、氯仿或氯苯;或者所述溶剂中的两种或更多种、典型地两种或三种的混合物。
一种优选的不同于C4-C7醇的另外的有机溶剂是丙酮。
在加入所述质子酸(HX)之前或之后可以加入额外的不同于C4-C7醇的另外的有机溶剂。所述质子酸(HX)甚至可以在与所述不同于C4-C7醇的另外的溶剂的混合物中加入。
在一个优选的方面,在加入所述质子酸(HX)之前,向被萃取的反应混合物中加入所述不同于C4-C7醇的另外的有机溶剂。
在一个进一步优选的方面,将溶液浓缩,然后加入质子酸(HX)。
可以将溶液通过蒸馏、例如通过共沸蒸馏浓缩。在所述C4-C7醇是1-丁醇的情况下,进行共沸蒸馏的温度在约70℃至回流温度之间,优选地在约80℃至约115℃之间,例如为约90℃、100℃或110℃。蒸馏可以在环境压力下或在减压下进行。
在一个进一步优选的方面,将溶液浓缩,然后加入所述不同于C4-C7醇的另外的有机溶剂,最后加入所述质子酸(HX)。
在混合物中所述C4-C7醇与上文所定义的另外的有机溶剂之间的比例可以典型地在约10:1(C4-C7醇的体积:另外的有机溶剂的体积,v:v)至1:10000(v:v)之间、优选地在约5:1(v:v)至约1:1000(v:v)之间、更优选地在约2:1(v:v)至约1:100(v:v)之间变化,例如比例为1:1(v:v)、1:2(v:v)、1:5(v:v)、1:10(v:v)或1:50(v:v)。在浓缩萃取溶液的情况下,所述比例是指在萃取溶液的浓缩步骤之后在混合物中的比例。
包含式(I)的牛磺熊去氧胆酸的萃取溶液的冷却可以在低于5℃的温度、优选在约0℃或更低的温度、例如在-5℃、-10℃或-20℃进行。可以将所述溶液缓慢冷却,例如以在约0.1-0.4℃/分钟之间的速度冷却。
质子酸(HX)的加入导致式(I)的牛磺熊去氧胆酸沉淀,但是不导致其它胆烷酸、特别是式(II)的熊去氧胆酸沉淀或者仅在微小程度上导致其它胆烷酸、特别是式(II)的熊去氧胆酸沉淀。
所述质子酸(HX)可以是无机酸或有机酸。
无机酸可以是例如选自硫酸、磷酸和氢卤酸的酸,优选盐酸。
有机酸可以是例如选自以下的酸:磺酸,典型地为樟脑磺酸、对甲苯磺酸、甲磺酸或三氟甲磺酸;芳基羧酸,典型地为苯甲酸;和C1-C4烷基羧酸,其中所述C1-C4烷基可以是直链的或支链的,并且任选地被一个或多个卤素原子、优选被1-3个氯或氟原子取代,典型地为乙酸或三氟乙酸。
质子酸(HX)可以以相对于式(I)的牛磺熊去氧胆酸而言约为化学计量的量、过量或不足量使用。典型地,对于每摩尔式(I)的牛磺熊去氧胆酸,质子酸(HX)可以是约0.5摩尔至约4.0摩尔,优选约0.5摩尔至约2.0摩尔,更优选约等摩尔的量,例如0.6摩尔、0.7摩尔、0.8摩尔、0.9摩尔、1.0摩尔、1.1摩尔、1.2摩尔、1.2摩尔、1.3摩尔、1.4摩尔、1.5摩尔、1.6摩尔、1.7摩尔、1.8摩尔、1.9摩尔、2.0摩尔、2.5摩尔、3.0摩尔、3.5摩尔或4.0摩尔质子酸(HX)/摩尔式(I)的牛磺熊去氧胆酸。
所述质子酸(HX)的加入可以在室温或者在低于或等于约20℃的温度、优选在约0℃至约20℃之间的温度、更优选在约5℃至约10℃之间的温度进行。作为替代选择,所述质子酸(HX)的加入可以在大于或等于约30℃、优选在约30℃至包含式(I)的牛磺熊去氧胆酸的混合物的回流温度之间的温度、例如在约40℃、在约50℃、在约60℃或在约70℃进行。
在之前不加入额外的不同于C4-C7醇的另外的有机溶剂的情况下,在室温或高于室温向式(I)的牛磺熊去氧胆酸的萃取溶液中加入质子酸(HX)不导致产物沉淀或者产物仅以低产率沉淀。因此,所述操作会使得该方法在工业水平上不实用。因此,在之前不加入额外的不同于C4-C7醇的另外的有机溶剂的情况下,加入质子酸(HX)典型地在低于约5℃的温度、优选在约0℃或更低的温度进行。
式(I)的牛磺熊去氧胆酸可以被进一步纯化,例如可以通过如IT 1197330或EP 2137 206中所述从水中结晶或者通过EP 0 629 634或EP 0 400 695中所述的色谱法被进一步纯化。
根据本发明的方法获得的式(I)的牛磺熊去氧胆酸的晶体的尺寸特征在于D90值在约5μm至约250μm之间,典型地低于100μm(通过Malvern Laser Diffraction Mastersizer3000和测量盒(measurement cell)Hydro 3000S测量)。如果需要,可以通过微粉化或精细研磨(fine milling)减小晶体的尺寸。
通过HPLC分析在195nm评价,根据本文所述的方法获得的式(I)的牛磺熊去氧胆酸的纯度令人惊奇地高于98%,例如纯度为98.5%、99.0%、99.5%或高于99.9%。
用作起始材料的式(I)的牛磺熊去氧胆酸可以从商业来源获得,或者可以是粗反应产物,其可以例如根据下述方法获得,所述方法包括:
a)用叔脂肪族或杂芳族胺使式(II)的熊去氧胆酸成盐:
b)将式(II)的熊去氧胆酸的盐用式(III)的衍生物处理:
Cl-COOR
(III)
其中Cl是氯且R选自C1-C6烷基、苯基或苄基;和
c)使步骤b)中获得的式(IV)的混合酸酐
其中R如上文所定义,
与式(V)的牛磺酸或其盐反应,
该反应任选地在碱存在下进行。
所述脂肪族叔胺或杂芳族胺的实例有三乙胺、三正丁基胺、甲基哌啶、乙基哌啶或吡啶。
式(V)的牛磺酸盐优选地为可药用盐。可药用盐的实例包括衍生自适宜的碱的盐,例如碱金属盐(例如钠盐或钾盐)、碱土金属盐(例如钙盐或镁盐)、铵盐或NR'4 +,其中R'是C1-C4烷基。
所述任选的碱可以是例如:无机碱,典型地为碱金属氢氧化物如氢氧化钠或氢氧化钾,或者碱土金属氢氧化物如氢氧化钙或氢氧化钡,更优选氢氧化钠、氢氧化钾或氢氧化钡。所述任选的碱可以是例如C1-C6醇盐,例如乙醇钠、乙醇钾、叔丁醇钠或叔丁醇钾;或者有机碱,例如叔胺,如三乙胺或二异丙基乙基胺。
下述实施例进一步举例说明本发明。
实施例1-式(I)的牛磺熊去氧胆酸的水溶液的制备
将160g(0.408摩尔)式(II)的熊去氧胆酸用在1200ml甲基异丁基酮中的约45.0g(0.448摩尔)三乙胺成盐。在不高于25℃的温度,将46g(0.42摩尔)氯甲酸乙酯加入到混合物中。将得到的反应混合物冷却至约0℃,加入溶于80ml水中的60g(0.40摩尔)牛磺酸的钠盐。在加入结束时,使混合物达到室温。分离水相,用80ml水洗涤有机相三次。合并水相,如下面的实施例中所述的那样纯化。
实施例2-式(I)的牛磺熊去氧胆酸的纯化
将320ml 1-丁醇加入到如实施例1中所述的那样获得的式(I)的牛磺熊去氧胆酸的水溶液中,弃去水相。丁醇萃取物样品的分析显示式(I)的牛磺熊去氧胆酸的含量为约30%,式(II)的熊去氧胆酸的含量为约3%-5%(通过HPLC分析在195nm评价)。向有机萃取混合物中加入约1500ml丙酮,随后加入40g HCl(37%)。将所得的沉淀的产物通过过滤分离并干燥,得到96g式(I)的牛磺熊去氧胆酸,产率为45%,其中式(II)的熊去氧胆酸的含量为0.16%。
实施例3-式(I)的牛磺熊去氧胆酸的纯化
将320ml 1-丁醇加入到实施例1中获得的式(I)的牛磺熊去氧胆酸的水溶液中,弃去水相。加入额外的480ml 1-丁醇,将有机混合物进行共沸蒸馏,直到水含量为5%或更少。将溶液加热至约50℃的温度,加入800ml丙酮,然后加入40g 37%HCl。将混合物保持在约50℃-60℃约6小时,然后冷却至室温。将所得的沉淀的产物通过过滤分离,用丙酮洗涤并干燥,得到190g式(I)的牛磺熊去氧胆酸,产率为80%。
Claims (10)
2.根据权利要求1所述的方法,其中所述C4-C7醇选自1-丁醇、仲-丁醇、叔-丁醇、1-戊醇、2-戊醇、3-戊醇、1-环己醇和1-庚醇,优选1-丁醇、2-丁醇、叔-丁醇和1-环己醇,更优选1-丁醇。
3.根据权利要求1或2所述的方法,其中所述不同于C4-C7醇的另外的有机溶剂选自:极性非质子溶剂,例如二甲基甲酰胺、二甲亚砜或乙腈;醚,例如甲基叔丁基醚、四氢呋喃或二噁烷;酮,例如甲基乙基酮、甲基异丁基酮或丙酮;酯,例如直链或支链的C1-C5醇的乙酸酯,优选乙酸乙酯;氯化溶剂,例如二氯甲烷、氯仿或氯苯;或者所述溶剂中的两种或更多种、典型地两种或三种的混合物。
4.根据权利要求3所述的方法,其中所述不同于C4-C7醇的另外的有机溶剂是丙酮。
5.根据权利要求1至4所述的方法,其中在加入所述质子酸(HX)之前,将所述溶液通过共沸蒸馏溶剂浓缩。
6.根据权利要求1至5所述的方法,其中所述质子酸(HX)是无机酸。
7.根据权利要求6所述的方法,其中所述无机酸选自硫酸、磷酸和氢卤酸,优选盐酸。
8.根据权利要求1至7所述的方法,其中所述纯化使用约0.5摩尔至约4.0摩尔、优选0.5摩尔至约2.0摩尔质子酸(HX)/摩尔式(I)的牛磺熊去氧胆酸、更优选在约等摩尔条件下进行。
9.根据权利要求1至8所述的方法,其中所述质子酸(HX)的加入在约0℃至所述溶液的回流温度之间的温度下进行。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102019000005906A IT201900005906A1 (it) | 2019-04-16 | 2019-04-16 | Procedimento di preparazione di coniugati di un acido colanico |
IT1020190000005906 | 2019-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111825737A true CN111825737A (zh) | 2020-10-27 |
Family
ID=67660623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010267936.6A Pending CN111825737A (zh) | 2019-04-16 | 2020-04-08 | 胆烷酸共轭物的纯化 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111825737A (zh) |
IT (1) | IT201900005906A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112645998A (zh) * | 2020-12-22 | 2021-04-13 | 重庆极泽生物科技有限公司 | 硼酸酯催化下合成牛磺熊去氧胆酸的方法 |
CN113583076A (zh) * | 2021-08-07 | 2021-11-02 | 浙江天顺药业有限公司 | 一种牛黄熊去氧胆酸及其制备方法 |
CN114539342A (zh) * | 2022-02-28 | 2022-05-27 | 成都百途医药科技有限公司 | 一种混合酸酐的制备方法及牛磺熊去氧胆酸二水物的工业化制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07267985A (ja) * | 1994-03-31 | 1995-10-17 | Tokyo Tanabe Co Ltd | タウロウルソデオキシコール酸水和物の製法 |
KR19980027016A (ko) * | 1996-10-14 | 1998-07-15 | 유충식 | 타우로우르소데옥시콜린산의 정제방법 |
CN101307088A (zh) * | 2008-07-08 | 2008-11-19 | 四川大学 | 一种胆酸偶联物的制备方法 |
US20100069654A1 (en) * | 2007-04-23 | 2010-03-18 | Massimo Parenti | Process for the preparation of tauroursodesoxycholic acid |
CN102718829A (zh) * | 2012-05-23 | 2012-10-10 | 杭州宝积生物科技有限公司 | 牛磺熊去氧胆酸钠的制备方法 |
CN103012539A (zh) * | 2012-12-10 | 2013-04-03 | 辽宁百凤生物药业有限公司 | 用含量98.5%的熊去氧胆酸生产牛磺熊去氧胆酸的生产方法 |
US20150017093A1 (en) * | 2012-02-03 | 2015-01-15 | Aarhus Universitet | Radiolabeled bile acids and bile acid derivatives |
CN105294809A (zh) * | 2015-12-21 | 2016-02-03 | 杭州和泽医药科技有限公司 | 一种牛磺熊去氧胆酸的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1197330B (it) | 1986-10-03 | 1988-11-30 | Prodotti Chimici Alimentari | Procedimento per la sintesi di acido tauroursodesossicolico biidrato |
IT1230796B (it) | 1989-05-30 | 1991-10-29 | Prodotti Chimici Alimentari | Procedimento per la preparazione di acido tauroursodesossicolico biidrato. |
IT1255486B (it) * | 1992-08-04 | 1995-11-06 | Erregierre Ind Chim | Processo per preparare gli acidi biliari coniugati con la taurina |
IT1270853B (it) | 1993-05-20 | 1997-05-13 | Sanofi Elf | Procedimento per la preparazione di derivati taurocolanici |
-
2019
- 2019-04-16 IT IT102019000005906A patent/IT201900005906A1/it unknown
-
2020
- 2020-04-08 CN CN202010267936.6A patent/CN111825737A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07267985A (ja) * | 1994-03-31 | 1995-10-17 | Tokyo Tanabe Co Ltd | タウロウルソデオキシコール酸水和物の製法 |
KR19980027016A (ko) * | 1996-10-14 | 1998-07-15 | 유충식 | 타우로우르소데옥시콜린산의 정제방법 |
US20100069654A1 (en) * | 2007-04-23 | 2010-03-18 | Massimo Parenti | Process for the preparation of tauroursodesoxycholic acid |
CN101307088A (zh) * | 2008-07-08 | 2008-11-19 | 四川大学 | 一种胆酸偶联物的制备方法 |
US20150017093A1 (en) * | 2012-02-03 | 2015-01-15 | Aarhus Universitet | Radiolabeled bile acids and bile acid derivatives |
CN102718829A (zh) * | 2012-05-23 | 2012-10-10 | 杭州宝积生物科技有限公司 | 牛磺熊去氧胆酸钠的制备方法 |
CN103012539A (zh) * | 2012-12-10 | 2013-04-03 | 辽宁百凤生物药业有限公司 | 用含量98.5%的熊去氧胆酸生产牛磺熊去氧胆酸的生产方法 |
CN105294809A (zh) * | 2015-12-21 | 2016-02-03 | 杭州和泽医药科技有限公司 | 一种牛磺熊去氧胆酸的制备方法 |
Non-Patent Citations (1)
Title |
---|
柴传柯: "牛磺熊去氧胆酸的合成工艺及工业化设计", 《中国优秀硕士学位论文全文数据库 工程科技I辑》, no. 7, pages 016 - 575 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112645998A (zh) * | 2020-12-22 | 2021-04-13 | 重庆极泽生物科技有限公司 | 硼酸酯催化下合成牛磺熊去氧胆酸的方法 |
CN112645998B (zh) * | 2020-12-22 | 2023-08-18 | 重庆极泽生物科技有限公司 | 硼酸酯催化下合成牛磺熊去氧胆酸的方法 |
CN113583076A (zh) * | 2021-08-07 | 2021-11-02 | 浙江天顺药业有限公司 | 一种牛黄熊去氧胆酸及其制备方法 |
CN114539342A (zh) * | 2022-02-28 | 2022-05-27 | 成都百途医药科技有限公司 | 一种混合酸酐的制备方法及牛磺熊去氧胆酸二水物的工业化制备方法 |
Also Published As
Publication number | Publication date |
---|---|
IT201900005906A1 (it) | 2020-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111825737A (zh) | 胆烷酸共轭物的纯化 | |
EP2024343B1 (en) | Process for purification of anastrozole | |
KR20100015633A (ko) | 타우로우르소데옥시콜린산 제조 공정 | |
EP1960416B1 (en) | Purification process for chenodeoxycholic acid | |
US20120165525A1 (en) | Process for the preparation of linagliptin | |
TW201429977A (zh) | 於製備式i之吡啶并吡咯烯(pyripyropene)化合物之方法 | |
BR112014014604B1 (pt) | processo para a preparação de um composto, e, composto isolado e purificado | |
US9663450B2 (en) | Process for the purification of melphalan | |
US7982062B2 (en) | Process for the preparation of cholanic acids | |
EP0678501B1 (en) | Process for producing N-chloroacetylglutamine | |
US9630987B2 (en) | Procedure for the preparation of abiraterone acetate and intermediates thereof | |
US20120022282A1 (en) | Process for the preparation of 2,4,6-octatriene-1-oic acid and 2,4,6-octatriene-1-ol | |
US20050090675A1 (en) | Process for preparing highly pure androstane 17-beta-carboxylic acids and 17-beta-carbothioic acid fluoromethyl esters thereof | |
EP3805244B1 (en) | Synthesis of glycoconjugate derivatives of a bile acid | |
CA2640242A1 (en) | A process for the preparation of polymorph form i of (s)-(+)-methyl-a-(2-chlorophenyl)-6,7-dyhidro-thieno-[3,2-c]pyridine-5(4h)-acetate hydrogen sulfate | |
EP3356372B1 (en) | Novel process for preparing thienopyrimidine compound and intermediates used therein | |
EP3486241B1 (en) | Method for producing crystal of uracil compound | |
JP2020070296A (ja) | リナグリプチンの製造法 | |
KR20160064139A (ko) | 소듐 하이오데옥시콜레이트 (NaHDC)의 다형 형태 및 그의 제조 방법 | |
US8329937B2 (en) | Method for purifying 4-(nitrooxy)butyl(2S)-2-(6-methoxy-2-naphthyl) propanoate | |
EP2768807B1 (en) | Processes for the preparation of 6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide and of its precursors | |
US10711030B2 (en) | Process for the preparation of allopregnanolone | |
CN106957311B (zh) | 雷替曲塞的溶剂化物及其制备方法 | |
WO2022195288A1 (en) | Process for the preparation of an n-acylethanolamide derivative | |
US8461190B2 (en) | Process for the purification of rufinamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40039393 Country of ref document: HK |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |